March 27, 2017
Nippon Shinyaku said on March 24 that it has acquired exclusive rights in Japan to develop and commercialize the investigational acute myeloid leukemia (AML) treatment DFP-10917 from Delta-Fly Pharma based in Tokushima. DFP-10917 is being developed for the treatment of...read more